x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DPP-001284
| Product Overview | |
|---|---|
| Species | Human |
| Expression System | Escherichia coli |
| Endotoxin Level | < 0.100 Eu/µg |
| Format | Lyophilized |
| Purity | ≥97% by SDS-PAGE |
| Nature | Recombinant |
| Target Information | |
|---|---|
| Gene Name | EGFL7 |
| UniProt No. | Q9UHF1 |
| Gene ID | 51162 |
| Molecular Weight | 27 kDa |
| Alternative Names | EGF like domain 7; EGF like domain containing protein 7; EGF like domain multiple 7; EGF-like protein 7; EGFL 7; EGFL7; EGFL7_HUMAN; Epidermal growth factor like domain protein 7; Epidermal growth factor-like protein 7; MEGF 7; MEGF7; MGC111117; Multiple EGF like domain protein 7; Multiple EGF-like domains protein 7; Multiple epidermal growth factor like domain protein 7; Multiple epidermal growth factor-like domains protein 7; NEU1; NEU1 protein; NOTCH4 like protein; NOTCH4-like protein; RP11 251M1.2; UNQ187/PRO1449; Vascular endothelial statin; VE statin; VE-statin; ZNEU 1; ZNEU1 |
| Function | Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cells adhesion to the substrate in vitro. |
| Cellular Localization | Secreted. |
| Protein Length | Full length protein |
| Sequence | MYRPGRRVCAVRAHGDPVSESFVQRVYQPFLTTCDGHRACSTYRTIYRTA YRRSPGLAPARPRYACCPGWKRTSGLPGACGAAICQPPCRNGGSCVQPGR CRCPAGWRGDTCQSDVDECSARRGGCPQRCVNTAGSYWCQCWEGHSLSAD GTLCVPKGGPPRVAPNPTGVDSAMKEEVQRLQSRVDLLEEKLQLVLAPLH SLASQALEHGLPDPGSLLVHSFQQLGRIDSLSEQISFLEEQLGSCSCKKD S,Contains 2 EGF-like domains. Contains 1 EMI domain. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped on dry ice. |
| Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
